Neurobo Stock Analysis


USD 1.40  0.05  3.45%   

The big decline in price over the last few months for Neurobo Pharmaceuticalsmay encourage institutional investors to take a closer look at the firm as it is trading at a share price of 1.40 on 424,151 in trading volume. The company directors and management failed to add value to investors and position the firm supply of money to exploit market volatility in November. However, diversifying your holdings with Neurobo Pharmaceuticals or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 23.78. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Neurobo Pharmaceuticals partners.
Additionally, see Correlation Analysis.
The Neurobo Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Neurobo Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Neurobo Stock analysis module also helps to analyze the Neurobo Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Neurobo Stock Analysis Notes

The company has price-to-book ratio of 1.68. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Neurobo Pharmaceuticals recorded a loss per share of 0.61. The entity last dividend was issued on the 31st of December 2019. The firm had 1:30 split on the 13th of September 2022. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company that develops and commercializes multimodal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts. Neurobo Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 5 people. To find out more about Neurobo Pharmaceuticals contact Ben MD at 857-702-9600 or learn more at

Neurobo Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Neurobo Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Neurobo Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Neurobo Pharmaceuticals generated a negative expected return over the last 90 days
Neurobo Pharmaceuticals has high historical volatility and very poor performance
Neurobo Pharmaceuticals may become a speculative penny stock
Net Loss for the year was (15.28 M) with profit before overhead, payroll, taxes, and interest of 0.
Neurobo Pharmaceuticals currently holds about 8.85 M in cash with (15.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow.

Neurobo Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Neurobo Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Neurobo Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report12th of November 2021
Next Financial Report21st of April 2022
Next Fiscal Quarter End30th of September 2021
Next Fiscal Year End21st of April 2022
Last Quarter Report30th of June 2021
Last Financial Announcement30th of September 2020

Neurobo Largest EPS Surprises

Earnings surprises can significantly impact Neurobo Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Neurobo Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 10.28 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Neurobo Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Neurobo Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (1.1014) % which means that it has lost $1.1014 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (2.2994) %, meaning that it created substantial loss on money invested by shareholders. Neurobo Pharmaceuticals management efficiency ratios could be used to measure how well neurobo pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 1st of December, Neurobo Pharmaceuticals secures the mean deviation of 13.8, and Risk Adjusted Performance of (0.043491). In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Neurobo Pharmaceuticals, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We have analyzed nineteen technical drivers for Neurobo Pharmaceuticals, which can be compared to its peers in the industry. Please verify Neurobo Pharmaceuticals jensen alpha and downside variance to decide if Neurobo Pharmaceuticals is priced some-what accurately, providing market reflects its recent price of 1.4 per share. Please also check out Neurobo Pharmaceuticals total risk alpha, which is currently at (1.86) to check the company can sustain itself at a future point.

Neurobo Pharmaceuticals Price Movement Analysis

The output start index for this execution was thirty-three with a total number of output elements of twenty-eight. Neurobo Pharmaceuticals Triple Exponential Moving Average indicator shows smoothing effect of Neurobo Pharmaceuticals price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.

Neurobo Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Neurobo Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Neurobo Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Neurobo Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Neurobo Pharmaceuticals Predictive Daily Indicators

Neurobo Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Neurobo Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Neurobo Pharmaceuticals Forecast Models

Neurobo Pharmaceuticals time-series forecasting models is one of many Neurobo Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Neurobo Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Neurobo Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Neurobo Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Neurobo shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Neurobo Pharmaceuticals. By using and applying Neurobo Stock analysis, traders can create a robust methodology for identifying Neurobo entry and exit points for their positions.
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company that develops and commercializes multimodal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts. Neurobo Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 5 people.

Current Neurobo Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Neurobo analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Neurobo analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
16.0Strong Buy1Odds
Neurobo Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Neurobo analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Neurobo stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Neurobo Pharmaceuticals, talking to its executives and customers, or listening to Neurobo conference calls.
Neurobo Analyst Advice Details

Neurobo Stock Analysis Indicators

Neurobo Pharmaceuticals stock analysis indicators help investors evaluate how Neurobo Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Neurobo Pharmaceuticals shares will generate the highest return on investment. By understating and applying Neurobo Pharmaceuticals stock analysis, traders can identify Neurobo Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow10089000.00
Common Stock Shares Outstanding540577.97
Total Stockholder Equity14597000.00
DescriptionNeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company that develops and commercializes multimodal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases. It develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19 NB-01 for the treatment of painful diabetic neuropathy NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated w
Total Cashflows From Investing Activities-586000.00
Property Plant And Equipment Net215000.00
Retained Earnings-81828000.00
Cash And Short Term Investments16387000.00
Accounts Payable830000.00
Net Debt-16316000.00
50 Day M A8.6069
Total Current Liabilities2157000.00
Currency CodeUSD
Non Current Assets Total215000.00
Additionally, see Correlation Analysis. Note that the Neurobo Pharmaceuticals information on this page should be used as a complementary analysis to other Neurobo Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Complementary Tools for Neurobo Stock analysis

When running Neurobo Pharmaceuticals price analysis, check to measure Neurobo Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurobo Pharmaceuticals is operating at the current time. Most of Neurobo Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Neurobo Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Neurobo Pharmaceuticals' price. Additionally, you may evaluate how the addition of Neurobo Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Money Managers
Screen money managers from public funds and ETFs managed around the world
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Bond Directory
Find actively traded corporate debentures issued by US companies
Is Neurobo Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurobo Pharmaceuticals. If investors know Neurobo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurobo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
10.3 M
Return On Assets
Return On Equity
The market value of Neurobo Pharmaceuticals is measured differently than its book value, which is the value of Neurobo that is recorded on the company's balance sheet. Investors also form their own opinion of Neurobo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Neurobo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurobo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Neurobo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurobo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Neurobo Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurobo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.